BeiGene, Ltd.'s latest marketcap:
As of 11/07/2026, BeiGene, Ltd.'s market capitalization has reached $44.25 B. According to our data, BeiGene, Ltd. is the 566th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 44.25 B |
| Revenue (ttm) | 6.61 B |
| Net Income (ttm) | 916.43 M |
| Shares Out | 0 |
| EPS (ttm) | 0.6 |
| Forward PE | 45.38 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/05/2026 |
BeiGene, Ltd.'s yearly market capitalization.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 11/07/2026 | HK$346.92 B | $44.25 B | 38.25% | 566 |
| 12/31/2025 | HK$261.67 B | $33.6 B | 71.29% | 609 |
| 12/31/2024 | HK$152.77 B | $19.66 B | 4.09% | 956 |
| 12/29/2023 | HK$146.76 B | $18.79 B | -17.6% | 942 |
| 12/30/2022 | HK$178.11 B | $22.8 B | -17.96% | 734 |
| 12/31/2021 | HK$217.12 B | $27.84 B | 19.19% | 727 |
| 12/31/2020 | HK$182.15 B | $23.49 B | 130.77% | 748 |
| 12/31/2019 | HK$78.93 B | $10.13 B | 21.11% | 1322 |
| 12/31/2018 | HK$65.17 B | $8.32 B | 101.8% | 1341 |
| 12/29/2017 | HK$32.3 B | $4.13 B | 254.84% | 2714 |
Company Profile
About BeiGene, Ltd.
BeiGene, Ltd. is an oncology-focused company dedicated to discovering and developing innovative treatments for cancer patients worldwide. Operating in the United States, China, Europe, and other international markets, the company is committed to advancing cancer care through cutting-edge therapies.
Commercial Stage Products
- BRUKINSA: A small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for treating various blood cancers.
- TEVIMBRA: An anti-PD-1 antibody immunotherapy targeting solid tumors and blood cancers.
- PARTRUVIX: A selective small molecule inhibitor of PARP1 and PARP2 enzymes, under evaluation for solid tumors.
Clinical Stage Products
BeiGene’s pipeline includes a diverse range of investigational therapies:
- Sonrotoclax (BGB-11417) – Bcl-2 inhibitor
- BGB-16673 – BTK-targeting chimeric degradation activation compound
- Ociperlimab (BGB-A1217) – TIGIT inhibitor
- BG-60366 – EGFR-targeted CDAC
- BG-89894 (SYH2039) – MAT2A Inhibitor
- BGB-58067 – MTA-Cooperative PRMT5 Inhibitor
- BG-T187 – Anti-EGFRxMET trispecific antibody
- BGB-26808 – HPK-1 Inhibitor
- BGB-C354 – Anti-B7H3 ADC
- Zanidatamab – Bispecific HER2-targeted antibody
- BG-C137 – Anti-FGFR2b ADC
- BGB-53038 – Pan-KRAS Inhibitor
- BGB-B2033 – Anti-GPC3x4-1BB bispecific antibody
- BGB-B3227 – Anti-MUC1xCD16A bispecific antibody
- BG-C477 – Anti-CEAADC
- BGB-43395 – CDK4 Inhibitor
- BG-68501 – CDK2 Inhibitor
- BG-C9074 – Anti-B7H4 ADC
- BGB-21447 – Bcl-2 Inhibitor
- BGB-45035 – IRAK4-targeted CDAC
Collaborations & Partnerships
BeiGene has strategic agreements with leading pharmaceutical companies, including:
- Amgen
- BMS
- Bio-Thera
- EUSA Pharma
- Luye Pharmaceutical
- Novartis
Company Background
Founded in 2010, BeiGene, Ltd. is headquartered in Camana Bay, the Cayman Islands. The company continues to expand its research and development efforts to address unmet medical needs in oncology.
Frequently Asked Questions
-
What is BeiGene, Ltd.'s (HKG-6160) current market cap?As of 11/07/2026, BeiGene, Ltd. (including the parent company, if applicable) has an estimated market capitalization of $44.25 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does BeiGene, Ltd. (HKG-6160) rank globally by market cap?BeiGene, Ltd. global market capitalization ranking is approximately 566 as of 11/07/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.